Current trends of anticancer immunochemotherapy. - Wikidata - wikimedia - TriplyDB

Current trends of anticancer immunochemotherapy.

Current trends of anticancer immunochemotherapy.

http://www.wikidata.org/entity/Q43084689

about

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer The clinical features and optimal treatment of anorectal malignant melanoma Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch: Peptide-based anticancer vaccines.Novel immune checkpoint blocker approved for the treatment of advanced melanoma Classification of current anticancer immunotherapies Combinatorial strategies for the induction of immunogenic cell death.Trial watch: Naked and vectored DNA-based anticancer vaccines Doubling the blockade for melanoma immunotherapy Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.Immunogenic cell death in radiation therapy Immunological effects of chemotherapy in spontaneous breast cancers.Trial Watch: DNA vaccines for cancer therapy.Trial Watch: Anticancer radioimmunotherapy.Trial Watch: Radioimmunotherapy for oncological indications.Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.

P2860

Q26795466-029FA39E-B8A6-4F45-9F2F-632DDD1E9140 Q26828599-CA29D611-11F2-464F-A599-8A2C5D1E7BC9 Q26996518-3A675037-A1B7-4E19-9CCA-3B30042BB749 Q27004011-E33B8D34-B706-4378-8A3D-213214DD9C05 Q27021951-B5EF9D0A-3B19-4FCA-9BDB-A1EB887F7F4A Q34483345-76F0CDAB-EB61-4602-B886-E4A84BB91592 Q34936394-FA5F8FF0-7B82-4FDB-BD92-F45D8EDD7D74 Q35149637-20ACAF97-8D42-4230-A664-70650FFA35C4 Q35535140-2998897E-0A87-43CC-A789-D90CFC52434E Q35798986-4E02ED29-30E3-44F3-8D3A-F17E81A3ACCD Q36597356-131BEDB6-3A72-4BBD-9621-D8EC23A20C8D Q41591613-276C46E7-F413-487D-96A3-935C40EE7875 Q41852251-CDC373A9-8DE0-4859-80AA-2D631E070324 Q41870388-8ACD5700-79D9-46C1-A7F9-CEBB3CB3E5F0 Q42552005-7339A8D4-E630-4BA1-80F2-95A48F982DBF Q42847992-AC73D4A2-92CD-499A-A4BD-905679BCD6E3 Q43104064-FF977C60-7D2E-4C9B-B982-D450F4F9206C Q50057949-369AA988-BBC0-4D63-9E3A-128DCC8B921C Q55057845-3E97F3B8-FA30-412B-96F9-1B6B4F5977FF

P2860

Current trends of anticancer immunochemotherapy.

http://www.wikidata.org/entity/Q43084689

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Current trends of anticancer immunochemotherapy.

@en

Current trends of anticancer immunochemotherapy.

@nl

type

label

Current trends of anticancer immunochemotherapy.

@en

Current trends of anticancer immunochemotherapy.

@nl

prefLabel

Current trends of anticancer immunochemotherapy.

@en

Current trends of anticancer immunochemotherapy.

@nl

P1433

Q43084689-FB88FC6F-4F47-42CA-BA4A-93B214284D42

P1476

Q43084689-75A9A0A9-BC82-4FC7-A9F9-067CEFC2E7E4

P2093

Q43084689-B6588829-0F59-466A-84B8-E7DDBCA5D57B

P2860

Q43084689-15AC387C-D4A2-4683-B7BD-51714E7F5620

Q43084689-1BD7166D-26D4-4E7C-8759-1B8D3FC0CA55

Q43084689-27A9BBCB-137E-4B32-A01D-D4422A00D51B

Q43084689-3E749160-97E1-48FF-B4CB-31967B404D6F

Q43084689-3F2841E1-0B6E-4D9C-A77B-A670C0600DAF

Q43084689-5E7A54D8-7010-403B-9BAA-41E0B9B10761

Q43084689-63353859-D7B8-450F-9A17-A31B4849E502

Q43084689-743BAA07-899C-4C49-AFB0-308B0EE9AF53

Q43084689-7847F96E-F26E-4F5C-AD49-1C195BC8E87E

Q43084689-7A1DB7B9-D926-4E98-A89D-C697F2BEE562

P304

Q43084689-2280A4DF-7967-401B-909F-FC0CC3143C31

P31

Q43084689-5ec17a43-b017-4e6c-9646-456f1f57edd9

Q43084689-8FE23E09-5B2D-44DE-9888-DE35E8AB268A

P356

Q43084689-7D7646B8-6E2B-430F-94E4-A32A0427E671

P433

Q43084689-B4FA6F44-195F-45F0-A321-367BDC017E99

P478

Q43084689-EF726B66-6A7D-4D1A-9AA2-E0C54D3D1C1F

P50

Q43084689-1FC83309-11B4-4970-A047-8615EBB940B1

Q43084689-875F6069-5F60-4F22-A6A0-9E264C1118F7

Q43084689-A85B690C-B59C-46F5-A439-CEE7824C65D7

P577

Q43084689-D9046018-2673-4869-AC6C-079D245D0ED7

P5875

Q43084689-AD342AED-E05E-4543-9C78-665F7052A1C8

P698

Q43084689-AB4781C8-95B5-47EE-AB1B-402AD3AD7FF5

P932

Q43084689-EC5F0007-A266-4102-B918-5434939BC065

P356

P1433

P1476

Current trends of anticancer immunochemotherapy.

@en

P2093

Nicole Prada

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenic cell death in cancer therapy

Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future.

Regulation of ligands for the NKG2D activating receptor.

Trial Watch: Monoclonal antibodies in cancer therapy

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.

Trial watch: Dendritic cell-based interventions for cancer therapy

Trial watch: Peptide vaccines in cancer therapy

Trial watch: DNA vaccines for cancer therapy.

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

P304

e25396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.25396

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Galluzzi

Erika Vacchelli

P577

2013-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

253336782

http://www.w3.org/2001/XMLSchema#string

P698

23894726

http://www.w3.org/2001/XMLSchema#string

P932

3716761

http://www.w3.org/2001/XMLSchema#string